TD Asset Management Inc Sells 65,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Key Points

• TD Asset Management Inc reduced its stake in Celldex Therapeutics by 45.2%, selling 65,000 shares and holding 78,878 shares valued at $1.43 million post-sale.
• Celldex Therapeutics reported a quarterly loss with an EPS of ($0.81), missing estimates, and a revenue of $0.70 million against analyst expectations of $1.08 million.
• The stock currently holds a consensus rating of "Moderate Buy" from analysts, with varying price targets ranging from $31.00 to $64.00.

TD Asset Management Inc lessened its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 45.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 78,878 shares of the biopharmaceutical company's stock after selling 65,000 shares during the period. TD Asset Management Inc owned 0.12% of Celldex Therapeutics worth $1,432,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Celldex Therapeutics by 6,665.9% in the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 2,933 shares during the period. Headlands Technologies LLC purchased a new stake in Celldex Therapeutics during the 4th quarter worth approximately $81,000. Aquatic Capital Management LLC bought a new stake in shares of Celldex Therapeutics in the 4th quarter worth about $121,000. Aristides Capital LLC acquired a new position in Celldex Therapeutics in the fourth quarter worth about $202,000. Finally, Hsbc Holdings PLC bought a new position in Celldex Therapeutics during the 4th quarter worth approximately $233,000.

Celldex Therapeutics Price Performance

CLDX stock traded down $0.12 during midday trading on Thursday, hitting $21.32. The company's stock had a trading volume of 561,746 shares, compared to its average volume of 928,012. The company's fifty day moving average price is $21.44 and its 200 day moving average price is $20.78. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The stock has a market capitalization of $1.42 billion, a P/E ratio of -7.92 and a beta of 1.22.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. The Goldman Sachs Group cut their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Celldex Therapeutics in a research report on Friday, June 13th. Canaccord Genuity Group started coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 price target on the stock. Morgan Stanley dropped their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Finally, UBS Group reduced their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.11.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.